Coherus Biosciences | CHRS - Işletim Giderleri





Işletim Giderleri Değişiklik Tarih
AbbVie USD 10.52B 258M 2026-09
Acadia Pharmaceuticals USD 270.57M 450K 2026-09
Akebia Therapeutics USD 63.08M 8.26M 2025-12
ALKERMES USD 1.86B 56.17M 2026-09
Alnylam Pharmaceuticals USD 1.11B 52.78M 2026-09
Amarin USD 51.48M 113K 2025-12
Amgen USD 5.69B 6B 2026-09
Baxter International USD 6.5B 3.82B 2026-09
Biogen USD 2.32B 663.6M 2026-09
BioMarin Pharmaceutical USD 819.04M 5.5B 2026-09
Bristol-Myers Squibb USD 23.4B 1.08B 2026-09
Coherus Biosciences USD 51.83M 2.48M 2025-12
Eli Lilly USD 10.52B 496M 2026-06
Fujifilm JPY 795.04B 19.73B 2026-09
Gilead Sciences USD 13.04B 9.09B 2026-09
Ironwood Pharmaceuticals USD 57.33M 8.63M 2024-12
Merck USD 10.75B 5.02B 2026-09
Myriad Genetics USD 212.8M 16.2M 2025-12
Pacira USD 1.18B 995.96M 2026-09
Perrigo USD 961.4M 670.9M 2026-09
Pfizer USD 89B 3.81B 2026-09
PTC Therapeutics USD 211.54M 15.12M 2026-06
Regeneron Pharmaceuticals USD 33.5B 1.79B 2026-09
Sarepta Therapeutics USD 390.39M 2.43M 2026-09
Teva Pharmaceutical Industries USD 3.18B 733M 2026-09
Vertex Pharmaceuticals USD 2.18B 118.2M 2026-09
Xencor USD 87.82M 5.44M 2026-06
Zoetis USD 3.3B 155M 2026-09